Georgi Mihaylov

Suggest Changes
Learn More
TPS225 Background: CFZ, a next-generation selective, irreversible epoxyketone proteasome inhibitor, has promising single-agent activity in relapsed/refractory (R/R) MM and a favorable side effect(More)
  • 1